At the recent 24th International Congress of The Transplantation Society (TTS) in Berlin, Organ Recovery Systems revealed the commercial prototype of its LifePort Liver Transporter, to the great interest of attending delegates.
A clinical feasibility study undertaken at Columbia University, New York, USA using an early prototype device has shown positive results in 35 livers donated from across the country, which were machine perfused prior to transplantation. The first 20 livers were from relatively low risk donors and the next 15 were marginal livers that had been turned down by transplant centers in the regions where the donors were located.
None of the livers experienced delayed graft function and only two patients (6%) developed complications associated with reperfusion injury, compared with the rate of 20% typically seen at Columbia University. One-year graft survival in the machine-perfused livers was 85.7%, compared with the anticipated graft survival of 75.8% expected of these types of livers based on their donor risk index, if they had been preserved using static cold storage. In patients whose liver had been machine perfused prior to transplantation the median length of hospital stay was 10 days, compared to 15 days for patients whose livers had been preserved in static cold storage.
Dr James Guarrera, Surgical Director, Adult Liver Transplantation and Assistant Professor of Surgery at Columbia University, who conducted the study, concluded that: "Our experience has demonstrated clinically that this new technology is a safe, effective and reliable technique to preserve livers prior to transplantation which reduces complications associated with ischemia / reperfusion injury and improves outcomes in liver transplantation."
* The LifePort Liver Transporter and disposable set are pending regulatory filing.